Abstract #1462

Preliminary Experience in Off-Label Use of Ferumoxytol Contrast-enhanced Magnetic Resonance Angiography in Pregnancy

Lindsay M Griffin¹, Kim-Lien Nguyen², Thomas M Grist¹, Christopher J Francois¹, Scott B Reeder³, J Paul Finn², and Mark L Schiebler¹

¹Radiology, University of Wisconsin, Madison, WI, United States, ²Radiology and Medicine, University of California Los Angeles, Los Angeles, CA, United States, ³Radiology, Medical Physics, Biomedical Engineering, Medicine, and Emergency Medicine, University of Wisconsin, Madison, WI, United States

Recent debate about potential long-term safety of gadolinium-based contrast agents has amplified concerns about their use in pregnancy, greatly limiting options for advanced imaging in this critical patient group. We report our experience on the use of ferumoxytol contrast-enhanced magnetic resonance angiography (MRA) during pregnancy. We identified eight pregnant subjects, at two institutions, with contrast-enhanced MRI/MRA using ferumoxytol. There was one mild possible adverse event during contrast administration. There were no premature deliveries (< 35 weeks) or birth defects in five babies with available postpartum data. While preliminary, ferumoxytol holds promise as a versatile MR contrast agent in pregnancy.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.